Oral AMXT 1501 Dicaprate in Combination With DFMO

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

December 30, 2022

Study Completion Date

April 21, 2023

Conditions
CancerSolid TumorSolid CarcinomaAdvanced Cancer
Interventions
DRUG

AMXT1501

AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules

DRUG

DFMO

DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules

Trial Locations (4)

22031

Virginia Cancer Center, Fairfax

77030

MD Anderson Cancer Center, Houston

78240

Next Oncology - San Antonio, San Antonio

78758

Next Oncology - Austin Midtown, Austin

Sponsors
All Listed Sponsors
lead

Aminex Therapeutics, Inc.

INDUSTRY